• NRX, an Israeli biotech company founded in 2020, is developing a novel drug delivery platform designed to provide minimally invasive, highly targeted solutions to address unmet medical needs.
  • The company leverages exosomes, tiny, naturally occurring cellular sacs, to deliver medication directly to inflamed or damaged tissues. This targeted approach offers potential advantages over traditional gene and cell therapies. While the exosome therapeutics industry is emerging, there are currently no FDA-approved products.